Abstract
Freshly isolated hepatocytes are currently regarded as the most superior in vitro model for use in prediction studies, in particular to provide estimates of in vivo intrinsic clearance (CLint). However, due to their loss of viability within 4 h and a decrease in cytochrome P450-dependent metabolism upon culture, newer cellular models are being developed. Cryopreserved hepatocytes have several potential advantages, but to date evaluation of the utility of this model for estimating in vitro CLint has been limited to the substrate depletion approach. We have incubated eight compounds with suspensions of freshly isolated and cryopreserved rat hepatocytes and obtained in vitro CLint via metabolite formation kinetics (for 14 pathways). A substantial range of in vitro CLint values (0.1–98 μl/min/106cells) was obtained in both models, and the freshly isolated suspension data were in good agreement with the literature. Cryopreserved suspensions were able to give a comparable estimation (within 2-fold) of in vitro CLint to fresh cells for six pathways, namely tolbutamide, three diazepam metabolites, propranolol, and 7-hydroxylation of warfarin. A higher estimation of in vitro CLint was obtained for the three other metabolites of warfarin due to a decrease in the KM values. Lower estimations of in vitro CLint were observed for four compounds (six pathways), and this was particularly pronounced (4–16%) for pathways showing atypical Michaelis-Menten kinetic profiles (dextromethorphan, nordiazepam) but less so (25–45%) for pathways showing biphasic Michaelis-Menten kinetics (7-ethoxycoumarin and phenytoin).
Footnotes
-
↵2 Abbreviations used are: CLint, intrinsic clearance; P450, cytochrome P450; TOL, tolbutamide; WAR, S-warfarin; PHE, phenytoin; 7-EC, 7-ethoxycoumarin; NDZ, nordiazepam; DZ, diazepam; DEX, dextromethorphan; PROP, propranolol; OXP, oxazepam; TZ, temazepam; 4′-OH DZ, 4′-hydroxydiazepam; 4′-OH NDZ, 4′-hydroxynordiazepam; HTOL, hydroxytolbutamide; MEM, methoxymorphinan; DOR, dextrorphan; FCS, fetal calf serum; DMF, dimethylformamide; EBSS, Earle balanced salt solution; WME, Williams medium E; BSA, bovine serum albumin; S50, substrate concentration at which half-maximal rate is observed for sigmoidal kinetics; 7-HC, 7-hydroxycoumarin; 4-OH PHE, 4-hydroxyphenytoin.
-
Financial support for this project was provided by Celltech R&D, United Kingdom. Part of this study was presented at the 6th International ISSX Meeting, October 7–11, 2001, Munich, Germany, and appeared in abstract form in Drug Metab Rev33 (Suppl 1):186 (2001).
-
↵1 Current address: Servier Research and Development, Fulmer Hall, Windmill Road, Fulmer, Slough, SL3 6HH, United Kingdom.
- Received December 12, 2003.
- Accepted February 5, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|